Market Overview:
Benztropine mesylate is a medication used to treat various movement disorders, including Parkinson's disease, dystonia, and akathisia. It is also used as an adjunct in the treatment of schizophrenia. It is available as an oral tablet and an injectable solution. The global benztropine mesylate market was valued at US$ 927 million in 2017 and is projected to reach US$ 1,584 million by 2030, registering a CAGR of 6.1% from 2018 to 2030.
Product Definition:
Benztropine mesylate is a medication used to treat various conditions including Parkinson's disease, dystonia, and vertigo. It works by blocking certain receptors in the brain that are responsible for causing these conditions. Benztropine mesylate is important because it can help improve the quality of life for those who suffer from these conditions.
Injection:
Injection is a drug form used to treat muscle spasticity due to multiple sclerosis, cerebral palsy or spinal cord injury. It works by blocking the release of certain chemicals in the brain that cause pain. Benztropine mesylate is an injectable form of benzotropine which is used for treating symptoms such as stiffness, walking problems and bladder control problems caused by multiple sclerosis.
Oral:
Oral is a form of drug delivery which involves the administration of drugs in pill or capsule form. The most commonly used route for delivering benztropine mesylate is oral route as it has a wide range of application and high patient compliance. Other routes of drug delivery include intravenous, intramuscular, and intraperitoneal.
Application Insights:
Based on the application, the benztropine mesylate market is segmented into Parkinsonism, extrapyramidal symptoms (EPS), and other applications. In 2017, Parkinsonism accounted for a larger share in terms of revenue as well as volume due to increasing incidence of PD. Increasing awareness about PD coupled with rising availability of advanced therapies such as deep brain stimulation is expected to increase demand for benztropine mesylate over the forecast period.
Extrapyramidal symptoms are also anticipated to witness significant growth owing to growing awareness among patients and increasing incidence rates over recent years. According to a study published by Healthline in 2018, it has been estimated that around 1 in 5 people aged 65 years or above suffer from EPS while around 1 in 10 people aged between 18-64 have reported experiencing some form of EPS during their lifetime. Thus, growing prevalence along with rising incidences is expected fuel demand for benztropine mesylate over the forecast period.
Regional Analysis:
North America dominated the global benztropine mesylate market in 2017. The presence of well-established healthcare facilities and a large patient pool are some of the major factors contributing to its largest share. Furthermore, increasing awareness regarding drug treatment options is also expected to drive this regional market over the forecast period.
Asia Pacific region is anticipated to witness lucrative growth during the forecast period owing to rising disposable income, improving healthcare infrastructure and an increase in medical tourism activities across various countries including India, China and Japan among others. Moreover, several multinational companies are investing huge amounts for research & development activities due to which Asia Pacific region will have a significant share by 2030 time frame as well.
Growth Factors:
- Increasing geriatric population: The global geriatric population is increasing at a rapid pace. This will lead to an increase in the number of patients suffering from Parkinson’s disease and other movement disorders, for which benztropine mesylate is prescribed.
- Growing awareness about the benefits of benztropine mesylate: There is growing awareness among doctors and patients about the benefits of benztropine mesylate therapy for treating movement disorders such as Parkinson’s disease. This will lead to an increase in its use in the coming years.
- Availability of generic versions: Benztropine mesylate is available as a generic drug, which makes it affordable for many people around the world who need it for treatment purposes. The availability of low-cost generic versions will help fuel market growth over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Benztropine Mesylate Market Research Report
By Type
Injection, Oral
By Application
Parkinsonism, Extrapyramidal Symptoms
By Companies
Akorn, Zydus Pharmaceuticals, ANI Pharmaceuticals, PLIVA, Fresenius Kabi, Hikma Pharmaceuticals, Cipla, Navinta, Aspen Pharmacare, Akorn
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
163
Number of Tables & Figures
115
Customization Available
Yes, the report can be customized as per your need.
Global Benztropine Mesylate Market Report Segments:
The global Benztropine Mesylate market is segmented on the basis of:
Types
Injection, Oral
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Parkinsonism, Extrapyramidal Symptoms
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Akorn
- Zydus Pharmaceuticals
- ANI Pharmaceuticals
- PLIVA
- Fresenius Kabi
- Hikma Pharmaceuticals
- Cipla
- Navinta
- Aspen Pharmacare
- Akorn
Highlights of The Benztropine Mesylate Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Injection
- Oral
- By Application:
- Parkinsonism
- Extrapyramidal Symptoms
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Benztropine Mesylate Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Benztropine mesylate is a medication used to treat symptoms of Parkinson's disease, such as tremors and difficulty walking. It is also used to prevent or reduce the severity of seizures in people with epilepsy. Benztropine mesylate is available in tablet form and as a liquid solution.
Some of the key players operating in the benztropine mesylate market are Akorn, Zydus Pharmaceuticals, ANI Pharmaceuticals, PLIVA, Fresenius Kabi, Hikma Pharmaceuticals, Cipla, Navinta, Aspen Pharmacare, Akorn.
The benztropine mesylate market is expected to register a CAGR of 6.1%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Benztropine Mesylate Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Benztropine Mesylate Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Benztropine Mesylate Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Benztropine Mesylate Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Benztropine Mesylate Market Size & Forecast, 2020-2028
4.5.1 Benztropine Mesylate Market Size and Y-o-Y Growth
4.5.2 Benztropine Mesylate Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Injection
5.2.2 Oral
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Parkinsonism
6.2.2 Extrapyramidal Symptoms
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Benztropine Mesylate Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Benztropine Mesylate Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Injection
9.6.2 Oral
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Parkinsonism
9.10.2 Extrapyramidal Symptoms
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Injection
10.6.2 Oral
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Parkinsonism
10.10.2 Extrapyramidal Symptoms
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Injection
11.6.2 Oral
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Parkinsonism
11.10.2 Extrapyramidal Symptoms
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Injection
12.6.2 Oral
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Parkinsonism
12.10.2 Extrapyramidal Symptoms
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Injection
13.6.2 Oral
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Parkinsonism
13.10.2 Extrapyramidal Symptoms
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Benztropine Mesylate Market: Competitive Dashboard
14.2 Global Benztropine Mesylate Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Akorn
14.3.2 Zydus Pharmaceuticals
14.3.3 ANI Pharmaceuticals
14.3.4 PLIVA
14.3.5 Fresenius Kabi
14.3.6 Hikma Pharmaceuticals
14.3.7 Cipla
14.3.8 Navinta
14.3.9 Aspen Pharmacare
14.3.10 Akorn
